FDA Approved Indications for this Orphan Drug:Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
FDA Marketing Approval issued as of:
Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
FDA Designation Date:
FDA Drug Designation:
Treatment of AIDS-related Kaposi's sarcoma.